PCA3 and prostate cancer: In this study, we quantify the expression of PCA3 in a large (n=12,076) localized prostate cancer cohort and relate these data to clinicopathological parameters, generating, to our knowledge, the largest study that correlates PCA3 expression to prostate cancer clinical outcome.